CPT code 82615 identifies a urine biochemical assay for cystine and homocystine, used to evaluate suspected cystinuria — an inherited disorder that predisposes patients to recurrent kidney stones and urinary tract infections. As a targeted diagnostic laboratory procedure, this test plays a role in confirming a metabolic cause of nephrolithiasis and guiding subsequent medical management and genetic counseling.

Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the test, typical sites of service, and the scope of services represented by this code. The publication outlines common billing and coding considerations, payer coverage patterns, and benchmarks where available. It also highlights policy issues that affect laboratory reimbursement and access to specialty metabolic testing.

This summary is intended for healthcare administrators, laboratory billing staff, and clinicians seeking a high-level reference on CPT code 82615. Readers can expect clear definitions, the clinical rationale for testing, and guidance on where to look for payer-specific coverage details. Data not available in the input is identified explicitly in relevant sections.